Clinical utility of lipoprotein-associated phospholipase A2 for cardiovascular disease prediction in a multiethnic cohort of women

Clinical Chemistry

Volumn 58, Issue 9, 2012, Pages 1352-1363

  Cook, Nancy R ^a   Paynter, Nina P ^a   Manson, JoAnn E ^a   Martin, Lisa W ^b   Robinson, Jennifer G ^c   Wassertheil Smoller, Sylvia ^d   Ridker, Paul M ^e  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^c UNIVERSITY OF IOWA   (United States)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE;

ADULT; AGED; ARTICLE; CALIBRATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COHORT ANALYSIS; ENZYME ACTIVITY; ENZYME ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MASS; PREDICTION; RISK; RISK FACTOR;

AGED; CARDIOVASCULAR DISEASES; COHORT STUDIES; ETHNIC GROUPS; FEMALE; HUMANS; LIPOPROTEINS; PHOSPHOLIPASES A2;

EID: 84865744110     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2012.188870     Document Type: Article

References (41)

1. Zalewski A, Nelson JJ, Hegg L, Macphee C. Lp- PLA2: a new kid on the block. Clin Chem 2006; 52:1645-50.
2. Caslake MJ, Packard CJ, Suckling KE, Holmes SD, Chamberlain P, Macphee CH. Lipoprotein-associated phospholipase A(2), plateletactivating factor acetylhydrolase: a potential new risk factor for coronary artery disease. Atherosclerosis 2000;150:413-9.
3. Gazi I, Lourida ES, Filippatos T, Tsimihodimos V, Elisaf M, Tselepis AD. Lipoprotein-associated phospholipase A2 activity in a marker of small, dense LDL particles in human plasma. Clin Chem 2005;51:2264 -73.
4. Khuseyinova N, Koenig W. Predicting the risk of cardiovascular disease: where does lipoprotein-associated phospholipase A2 fit in? Mol Diag Ther 2007;11:203-17.
5. The Lp-PLA2 Studies Collaboration, Thompson A, Gao P, Orfei L, Watson S, Di Angelantonio E, Kaptoge S, et al. Lipoprotein-associated phospholipase A2 and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet 2010;375:1536-44.
6. Stein E. Lipoprotein-associated phospholipase (Lp-PLA2) measurements: mass, activity but little productivity. Clin Chem 2012:58:814 -7.
7. Langer RD, White E, Lewis CE, Kotchen JM, Hendrix SL, Trevisan M. The Women's Health Initiative Observational Study: baseline characteristics of participants and reliability of baseline measures. Ann Epidemiol 2003;13:S107-21.
8. The Women's Health Initiative Study Group. Design of the Women's Health Initiative clinical trial and observational study. Contr Clin Trials 1998; 19:61-109.
9. Women's Health Initiative Investigators, Margolis KL, Lihong Qi, Brzyski R, Bonds DE, Howard BV, Kempainen S, et al. Validity of diabetes selfreports in the Women's Health Initiative: comparison with medication inventories and fasting glucose measurements. Clin Trials 2008;5:240 -7.
10. Curb JD, McTiernan A, Heckbert SR, Kooperberg C, Stanford J, Nevitt M, et al. Outcomes ascertainment and adjudication methods in the Women's Health Initiative. Ann Epidemiol 2003;13: S122- 8.
11. Prentice RL. A case-cohort design for epidemiologic cohort studies and disease prevention trials. Biomka 1986;73:1-11.
12. Borgan O, Langholz B, Samuelson SO, Goldstein L, Pogoda J. Exposure stratified case-cohort designs. Lifetime Data Anal 2000;6:39 -58.
13. Barlow WE. Robust variance estimation for the case-cohort design. Biom 1994;50:1064 -72.
14. Therneau TM, Li H. Computing the Cox model for case cohort designs. Lifetime Data Anal 1999;5: 99-112.
15. Langholz B, Jiao J. Computational methods for case-cohort studies. Comp Stat Data Anal 2007; 51:3737- 48.
16. Ridker PM, Buring JE, Rifai N, Cook NR. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women. JAMA 2007;297:611-9.
17. Blake GJ, Dada N, Fox JC, Manson JE, Ridker PM. A prospective evaluation of lipoprotein-associated phospholipase A(2) levels and risk of future cardiovascular events in women. J Am Coll Cardiol 2001;38:1302- 6.
18. Wassertheil-Smoller S, Kooperberg C, McGinn AP, Kaplan RC, Hsia J, Hendrix SL, et al. Lipoprotein-associated phospholipase A2, hormone use, and the risk of ischemic stroke in postmenopausal women. Hypertens 2008;51:1115-22.
19. Noto H, Chitkara P, Raskin P. The role of lipoprotein-associated phospholipase A(2) in the metabolic syndrome and diabtetes. J Diab Compl 2006;20:343- 8.
20. Pencina MJ, D'Agostino RBS, D'Agostino RBJ, Vasan RS. Evaluating the added predictive ability of a new biomarker: from area under the ROC curve to reclassification and beyond. Stat Med 2008;27:157-72.
21. Cook NR. Use and misuse of the receiver operating characteristic curve in risk prediction. Circ 2007;115:928 -35.
22. Cook NR, Ridker PM. Advances in measuring the effect of individual predictors of cardiovascular risk: the role of reclassification measures. Ann Intern Med 2009;150:795- 802.
23. Cook NR, Buring JE, Ridker PM. The effect of including C-reactive protein in cardiovascular risk prediction models for women. Ann Intern Med 2006;145:21-9.
24. Chambless LE, Cummiskey CP, Cui G. Several methods to assess improvement in risk prediction models: extension to survival analysis. Stat Med 2010;30:22-38.
25. Pencina MJ, D'Agostino RB Sr, Steyerberg EW. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med 2011;30:11-21.
26. Khuseyinova N, Imhof A, Rothenbacher D, Trischler G, Kuelb S, Scharnagl H, et al. Association between Lp-PLA2 and coronary artery disease: focus on its relationship with lipoproteins and markers of inflammation and hemostasis. Atherosclerosis 2005;182:181- 8.
27. Ballantyne CM, Hoogevenn RC, Bang H, Coresh J, Folsom AR, Heiss G, Sharrett AR. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) Study. Circ 2004;109:837- 42.
28. Caslake MJ, Packard CJ, Robertson M, Cooney J, Nelson JJ, et al. for the PROSPER Study Group. Lipoprotein-associated phospholipase A(2), inflammatory biomarkers, and risk of cardiovascular disease in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER). Atherosclerosis 2010;210:28 -34.
29. Ridker PM, MacFadyen JG, Wolfert RL, Koenig W. Relationship of lipoprotein-associated phospholipase A2 (Lp-PLA2) mass and activity with incident vascular events among primary prevention patients allocated to placebo or to statin therapy: an analysis from the JUPITER Trial. Clin Chem 2012;58:877- 86.
30. Packard CJ, O'Reilly DSJ, Caslake MJ, McMahon AD, Ford I, Cooney J, et al. For the West of Scotland Coronary Prevention Study Group. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. N Engl J Med 2000;343:1148 -55.
31. Koenig W, Khuseyinova N, Lowel H, Trischler G, Meisinger C. Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow-up of a large cohort from southern Germany. Circ 2004; 110:1903- 8.
32. Oei HH, van der Meer IM, Hofman A, Koudstaal PJ, Stijnen T, Breteler MMB, Witteman JCM. Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study. Circ 2005;111:570 -5.
33. Ballantyne CM, Hoogevenn RC, Bang H, Coresh J, Folsom AR, Chambless LE, et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) Study. Arch Intern Med 2005;165:2479-84.
34. Persson M, Hedblad B, Nelson JJ, Berglund G. Elevated Lp-PLA2 levels add prognostic information to the metabolic syndrome on incidence of cardiovascular events among middle-aged nondiabetic subjects. Aterioscler Thromb Vasc Biol 2007;27:1411-16.
35. Wassertheil-Smoller S, McGinn A, Allison MA, Cai T, Curb D, Eaton C, et al. Improvement in stroke risk prediction: role of C-reactive protein (CRP) and lipoprotein-associated phospholipase A2 (Lp- PLA2) in the Women's Health Initiative. Int J Stroke. Forthcoming 2012.
36. McConnell JP, Jaffe AS. Variability of lipoprotein-associated phospholipase A2 measurements. Clin Chem 2008;54:932-3.
37. Daniels LB, Laughlin GA, Sarno MJ, Bettencourt R, Wolfert RL, Barrett-Connor E. Lipoprotein-associated phospholipase A2 is an independent predictor of incident coronary heart disease in an apparently healthy older population: the Rancho Bernardo Study. J Am Coll Cardiol 2008;51:913-9.
38. Iribaren C, Gross MD, Darbinian JA, Jacobs DR, Sidney S, Loria CM. Association of lipoprotein-associated phospholipase A2 mass and activity with calcified coronary plaque in young adults: the CARDIA study. Arterioscler Thromb Vasc Biol 2005;25:216 -21.
39. Jenny NS, Solomon C, Cushman M, Tracy RP, Nelson JJ, Psaty BM, Furberg CD. Lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) and risk of cardiovascular disease in older adults: results from the Cardiovascular Health Study. Atherosclerosis 2010;209:528 -32.
40. Davidson MH, Corson MA, Alberts MJ, Anderson JL, Gorelick PB, Jones PH, et al. Consensus panel recommendation for incorporating lipoproteinassociated phospholipase A2 testing into cardiovascular disease risk assessment guidelines. Am J Cardiol 2008;101(Suppl):51-7F.
41. Oliver LK, Voskoboev N, Heser D, McConnell JP, Hodel-Hanson S, Callanan H, Jaffe AS. Assessment of clinical performance without analytical validation: a prescription for confusion. Clin Biochem 2011;44:1247-52.